Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06769867
Starting soon Not applicable

(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction

NCT06769867 · tracked via the Priya Life Science China tracker
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Not applicable
Started
2025-04-15
Last updated
2025-03-18

Condition(s) studied

Cerebrovascular Disease

Investigational drug(s) / intervention(s)

PS-3D-DSAclassic 3D-DSA

PS-3D-DSA: undergo a PS-3D-DSA scan

classic 3D-DSA: undergo a classic 3D-DSA scan

Study summary

If the participants agree to participate in this study, the participants will undergo two scans (classic 3D-DSA and PS-3D-DSA assisted scan) to compare the imaging effects of both. After the procedure, the investigators will record the radiation exposure and collect DSA images.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age ≥18 years. 2. Requires 3D-DSA-guided interventional diagnosis or treatment (e.g., cerebral angiography, cerebral artery chemoembolization) and meets operational indications. 3. Can understand the study's purpose, procedures, potential risks, and benefits, and voluntarily signs a written informed consent form. Exclusion Criteria: 1. Severe heart or lung disease, such as heart failure or chronic obstructive pulmonary disease (COPD). 2. History of high-dose radiation exams or treatments. 3. Known allergies or severe adverse reactions to iodine contrast agents or other relevant medications. 4. Pregnant or breastfeeding women. 5. Severe comorbidities or chronic diseases (e.g., severe diabetes, renal insufficiency). 6. Severe mental illness or cognitive impairment preventing understanding of the study procedures or providing informed consent.

Primary outcome measure(s)

  • The radiation dose received by patients during interventional procedures when using two scanning protocols (classic 3D-DSA and PS-3D-DSA) — No more than 6 hours
    Using the built-in radiation monitoring function of interventional surgical equipment (DSA system), the radiation dose (AK，air kerma) received by the patient during the procedure is directly measured and recorded. The collected radiation dose data is documented in the patient's medical records and stored in the research database for subsequent analysis and comparative studies.

Trial sites (1)

FacilityCityRegionStatus
Wuhan Union Hospital Wuhan Hubei

More Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials in China

Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain. Recruiting
Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging Starting soon
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM Recruiting
Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE Recruiting
Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer Recruiting

Other trials for the same condition

Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) Enrolling by invitation
Multi-Modality Imaging Standard Cohort Of Cerebrovascular Disease Recruiting
The Analgesic Effect of Scalp Nerve Block Using Bupivacaine Liposomes for Postoperative Pain Relief After Craniotomy Recruiting
Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care Recruiting
Application of QDSA Platform in Cerebrovascular Diseases Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06769867 on ClinicalTrials.gov ↗ ← All trials in China